Granite Investment Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Granite Investment Partners’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-231,917	Closed	-$9.33M	–	278
2026 Q1	$9.33M	Sell	231,917 -95,177	-29%	-$2.05M	0.57%	61
2025 Q4	$8.22M	Buy	+327,094	New	+$7.67M	0.49%	76

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Granite Investment Partners's APLS Position: Q2 2026 in Review

Granite Investment Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 231,917 shares — an estimated $9.33M sold.

Granite Investment Partners first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $9.33M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Granite Investment Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Granite Investment Partners sold 231,917 Apellis Pharmaceuticals shares in Q2 2026, an estimated $9.33M.
Granite Investment Partners first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Granite Investment Partners's Apellis Pharmaceuticals position peaked at $9.33M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Granite Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.